Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loratadine for Pegfilgrastim-Induced Bone Pain in Lymphoma
NCT02392039Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2015
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of loratadine in bone pain (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Functional Assessment of Cancer Therapy-Bone Pain at 26 weeks. Started Dec 2015; status: terminated.
02
Drugs
loratadine
03
Conditions
bone pain
Beyond the preview
Go deeper on NCT02392039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392039.